Search results
Results from the WOW.Com Content Network
Sofosbuvir/velpatasvir was developed by the pharmaceutical company Gilead Sciences and approved by the U.S. Food and Drug Administration (FDA) in June 2016. [13] In the European Union it was approved in July 2016, for the treatment of chronic hepatitis C virus infection in adults.
Velpatasvir reaches highest blood plasma levels three hours after oral intake together with sofosbuvir. Plasma protein binding is over 99.5%. It is slowly metabolised by the liver enzymes CYP2B6, CYP2C8 and CYP3A4.
The U.S. Food and Drug Administration is asking a panel of experts to weigh in on a women's version of the male sexual dysfunction drug Viagra. The FDA is considering Boehringer Ingelheim's drug ...
In 2000, Viagra sales accounted for 92% of the global market for prescribed erectile dysfunction pills. [77] By 2007, Viagra's global share had plunged to about 50% [78] due to several factors, including the entry of Cialis and Levitra, along with several counterfeits and clones, and reports of vision loss in people taking PDE5 inhibitors.
For premium support please call: 800-290-4726 more ways to reach us
A panel of U.S. Food and Drug Administration experts decided Friday that Boehringer Ingelheim's so-called "female viagra" drug, flibanserin, doesn't provide enough benefit to outweigh the risks.
A New Drug Application of bremelanotide for female sexual dysfunction was accepted by the US Food and Drug Administration (FDA) in June 2018, with a Prescription Drug User Fee Act (PDUFA) goal date set for 23 March 2019. [30] It was approved for use in the United States in June 2019. [3] [31] [32]
The U.S. Food and Drug Administration (FDA) has approved several medications for the treatment of ED, including: Sildenafil (the active ingredient in Viagra or generic versions of Viagra ...